Wilson Nick, Mansoor Osman, Wenger Jay, Martin Rebecca, Zanardi Lynn, O'Leary Michael, Rabukawaqa Vilikesa
367a Karori Road, Karori, Wellington, New Zealand.
Vaccine. 2003 May 16;21(17-18):1907-12. doi: 10.1016/s0264-410x(02)00825-3.
To estimate Haemophilus influenzae type b (Hib) disease burden in Fiji in children under the age of 5 years (under-5s) prior to vaccine introduction. To compare estimates from WHO's Hib rapid assessment tool (RAT), with that from decline in disease after vaccine introduction.
Laboratory data (meningitis), hospitalization and mortality data (pneumonia and meningitis) before and after Hib vaccine introduction were collected. The RAT protocol provides two independent estimates of pre-vaccine disease burden (one based on meningitis incidence laboratory data and the other based on mortality statistics). A third estimate uses the decline in disease following vaccine introduction.
The decline in meningitis hospitalizations implies a pre-vaccine Hib meningitis incidence of 66 per 100,000 in under-5s. This compares with a pre-vaccine RAT estimate of Hib meningitis incidence of 84 per 100,000 (for 1992-1993). The RAT estimated the total annual pre-vaccine Hib burden (meningitis plus pneumonia) at 476 cases and 36 deaths per year ("meningitis incidence method") and 70 cases and 5 deaths ("child mortality method"). Hib vaccine led to declines of 32% (95% confidence interval (CI)=11-48%), and 78% (95% CI=22-94%) for all under-5s meningitis hospitalizations and deaths, respectively. There was no similar consistent decline in pneumonia hospitalizations or deaths after vaccine introduction, except for a statistically significant reduction in pneumonia mortality in children aged under 1 year.
Hib disease constitutes an important burden on the health of Pacific children that can be rapidly reduced with Hib vaccine. In this setting, routine morbidity statistics (comparing pre-and post-vaccine) provided an estimate of Hib meningitis burden which is broadly similar to that of the Hib RAT, suggesting that both might be valid ways to estimate Hib meningitis incidence. However, Hib pneumonia burden could not be estimated from routine statistics.
评估斐济在引入疫苗前5岁以下儿童中b型流感嗜血杆菌(Hib)疾病负担。比较世界卫生组织Hib快速评估工具(RAT)的估计值与引入疫苗后疾病下降情况的估计值。
收集了引入Hib疫苗前后的实验室数据(脑膜炎)、住院和死亡数据(肺炎和脑膜炎)。RAT方案提供了两种独立的疫苗接种前疾病负担估计值(一种基于脑膜炎发病率实验室数据,另一种基于死亡率统计数据)。第三种估计值使用引入疫苗后疾病的下降情况。
脑膜炎住院人数的下降意味着5岁以下儿童中疫苗接种前Hib脑膜炎发病率为每10万人66例。相比之下,RAT对疫苗接种前Hib脑膜炎发病率的估计为每10万人84例(1992 - 1993年)。RAT估计疫苗接种前Hib的年度总负担(脑膜炎加肺炎)为每年476例和36例死亡(“脑膜炎发病率法”)以及70例和5例死亡(“儿童死亡率法”)。Hib疫苗使所有5岁以下儿童的脑膜炎住院人数和死亡人数分别下降了32%(95%置信区间(CI)=11 - 48%)和78%(95% CI = 22 - 94%)。引入疫苗后,肺炎住院人数或死亡人数没有类似的持续下降,除了1岁以下儿童的肺炎死亡率有统计学显著降低。
Hib疾病对太平洋地区儿童的健康构成了重要负担,通过Hib疫苗可迅速减轻。在这种情况下,常规发病率统计数据(比较疫苗接种前后)提供的Hib脑膜炎负担估计值与Hib RAT的估计值大致相似,这表明两者可能都是估计Hib脑膜炎发病率的有效方法。然而,无法从常规统计数据中估计Hib肺炎负担。